Document:

EX-10.9

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Exhibit 10.9 
 License
Agreement 
 Execution Copy, Immatics August 3rd 2015 
  

NON-EXCLUSIVE LICENSE AGREEMENT 

Between: 
 STICHTING SANQUIN BLOEDVOORZIENING 

as Licensor 
 and 

IMMATICS BIOTECHNOLOGIES GMBH 
 as Licensee 

  

							
	License Agreement	    		  	 Page
 1
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

 NON-EXCLUSIVE LICENSE AGREEMENT 

This NON-EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of August 3rd, 2015 (the
“Effective Date”) by and between 
 STICHTING SANQUIN BLOEDVOORZIENING, a foundation organized and existing under the laws of the
Netherlands, having its address at Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands (“SANQUIN”); 
 and 

IMMATICS BIOTECHNOLOGIES GMBH, a limited liability company organized and existing under the laws of Germany, having its address at Paul-Ehrlich-Strasse 15,
72076 Tuebingen, Germany (“IMMATICS”); 
 SANQUIN and IMMATICS are referred to herein individually as a “Party” and
collectively as the “Parties”. 
 WHEREAS: 
  

	A.	 IMMATICS is a clinical-stage biopharmaceutical company engaged in the research, development,
manufacturing and commercialization of, among others, advanced immunotherapies that are active against cancer; 

  

	B.	 SANQUIN possesses certain intellectual property rights to a technology for breaking non-covalent binding interactions between molecules and a technology to detect antigen responsive cells in a sample (the “Sanquin Patent Rights” as defined in more detail below);

  

	C.	 IMMATICS desires to license from SANQUIN the Sanquin Patent Rights to apply this technology in its own
development programs and in partnered programs; 

  

	D.	 SANQUIN desires to grant such a license on a non-exclusive basis
to IMMATICS in accordance with the terms and conditions of this Agreement 

  

							
	License Agreement	    		  	 Page
 2
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

 THEREFORE, IT IS AGREED AS FOLLOWS: 

 

	1.	 DEFINITIONS 

As used in this Agreement, the following terms shall have the following meanings: 
  

			
		
	Affiliate	  	means any corporation or other entity, which directly or indirectly controls, is controlled by or is under common control with a Party. A corporation or other entity shall be regarded as in control of another corporation or entity
if it owns or directly or indirectly controls more than fifty percent (50%) of the voting stock or other ownership interest of the other corporation or entity, or if it possesses, directly or indirectly, the power to direct or cause the direction of
the management and policies of the corporation or other entity or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other entity.
		
	Agreement	  	this non-exclusive license agreement;
		
	Business Days	  	shall mean a day that is not a Saturday, Sunday or public holiday in Tuebingen or Amsterdam
		
	Confidential Information	  	means all information that has been or will be disclosed by or on behalf of that Party (the “Disclosing Party”), to the other Party (the “Receiving Party”), directly or indirectly, in whatever form,
including (without limitation) any data, reports, analyses, specifications, techniques, processes, technical information, ideas, know-how, trade secrets, patents, patent applications and inventions (whether or
not patentable), drawings, designs and computer software, and which is marked as confidential; for the avoidance of doubt, Immatics Improvements are deemed Confidential Information of IMMATICS and Sanquin Improvements are deemed Confidential
Information of SANQUIN;
		
	Covenant Not To Sue	  	has the meaning set forth in Section 3.3;
		
	Effective Date	  	has the meaning set forth in the Preamble;
		
	Field	  	means research and development of drugs in oncology and infectious diseases, including immunomonitoring and other fee-for-service services;
IMMATICS may not manufacture for sale or distribution to Third Parties materials or reagents covered by Sanquin Patent Rights;

  

							
	License Agreement	    		  	 Page
 3
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

			
		
	Immatics Improvement	  	means any invention that constitutes a modification, enhancement, new use or improvement to the technology claimed in the Sanquin Patent Rights that is conceived or reduced to practice by IMMATICS during the Term and the use of
which would infringe one or more Valid Claims of the Sanquin Patent Rights if no license under the Sanquin Patent Rights would have been granted thereunder;
		
	Immatics Improvement Patent	  	means any patents or patent applications claiming an Immatics Improvement
		
	Improvement	  	means an Immatics Improvement or a Sanquin Improvement, whatever the case may be
		
	IP Status	  	means the status of the Sanquin Patent Rights as of the Effective Date as set forth in Schedule 1
		
	License Fee	  	has the meaning as set forth in Section 4.2
		
	Major European Countries	  	means the following countries: GB, FR, DE, IT, ES, CH
		
	Sanquin Improvement	  	means any invention that constitutes a modification, enhancement, new use or improvement to the technology claimed in the Sanquin Patent Rights that is conceived or reduced to practice by SANQUIN during the Term and the use of which
would, if such use was done by a Third Party, infringe one or more Valid Claims of the Sanquin Patent Rights if no license under the Sanquin Patent Rights would have been granted thereunder and, for the avoidance of doubt, that does not have the
same priority as the Sanquin Patent Right 1 or the Sanquin Patent Right 2
		
	Sanquin Improvement Patent	  	means any patents or patent applications claiming a Sanquin Improvement

  

							
	License Agreement	    		  	 Page
 4
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

			
		
	Sanquin Patent Rights	  	means (i) the patents and applications included in patent family WO 2006/080837, including but not limited to EP1841791, (Means and methods for breaking noncovalent binding interactions between molecules) (collectively
“Sanquin Patent Right 1”), and
		
	 	  	(ii) patent and patent applications included in patent family WO 2010/060439, including but not
limited to EP2362882 (Detecting antigen responsive cells in a sample) (collectively “Sanquin Patent
Right
2”);
		
	 	  	(iii) including with regard to (i) and (ii), without limitation, all provisional applications, substitutions,
continuations,
continuations-in-part, divisions, and renewals, all letters patent granted thereon, and
all
patents-of-addition, reissues, re-examinations and extension or restorations by existing or future
extension or restoration
mechanisms, including, without limitation supplementary protection
certificates or the equivalent thereof, and
		
	 	  	(iv) all patent applications that may hereafter be filed by or on behalf of SANQUIN which claim
priority from any of the foregoing patents and applications;
		
	Service Fee	  	has the meaning as set forth in Section 4.4;
		
	Term	  	means the term of this Agreement as set forth in Section 5.1;
		
	Territory	  	means the world;
		
	Third Party	  	means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, other entity or body, or an individual; other than
SANQUIN and IMMATICS and their Affiliates;
		
	Valid Claim	  	means a claim of (a) an issued, unexpired patent which has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be
taken, or with respect to which an appeal is not taken within the time allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) any patent
application which has not been cancelled, withdrawn, or abandoned.

		
	Yearly Increase Percentage	  	has the meaning as set forth in Section 4.3;

  

							
	License Agreement	    		  	 Page
 5
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	2.	 LICENSE 

  

	2.1.	 SANQUIN hereby grants to IMMATICS and IMMATICS hereby accepts a
non-exclusive, non-transferable license in the Field and in the Territory to use: 

 

	 	a.	 the Sanquin Patent Rights 1; and 

 

	 	b.	 the Sanquin Patent Rights 2. 

 

	2.2.	 The license shall not be sub-licensable without consent of SANQUIN
except to Affiliates. 

  

	3.	 PATENT PROSECUTION AND ENFORCEMENT / IMPROVEMENTS 

 

	3.1.	 Patent Prosecution and Maintenance. SANQUIN shall remain responsible for preparing, filing, prosecuting,
handling, and maintaining the Sanquin Patent Rights during the Term, at its expense and its reasonable discretion and will within 15 Business Days after Sanquin becomes aware of a change of the IP Status inform IMMATICS in writing of such change.

  

	3.2.	 Patent Enforcement and Defense. If IMMATICS learns of any substantial infringement of the Sanquin Patent
Rights by a Third Party in the Field or learns about a (threatened) challenge of the Sanquin Patent Rights by a Third Party in the form of invalidity actions, oppositions or otherwise, IMMATICS shall so inform SANQUIN and provide SANQUIN with
reasonable evidence of the infringement, or, respectively, challenge. If SANQUIN learns of any substantial infringement of the Sanquin Patent Rights by a Third Party or learns about a (threatened) challenge of the Sanquin Patent Rights by a Third
Party in the form of invalidity actions, oppositions or otherwise, SANQUIN shall so inform IMMATICS in writing and provide IMMATICS with reasonable evidence of the infringement or, respectively, challenge. SANQUIN shall have the first right (but not
the obligation) to take action against any infringer of the Sanquin Patent Rights at its costs if in Sanquin’s reasonable discretion such actions are justified from a commercial and legal perspective and shall keep IMMATICS reasonably informed
of the progress of such action and of any infringement suit, including of any completion or settlement of such action or suit. 

  

							
	License Agreement	    		  	 Page
 6
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	3.3.	 Covenant Not to Sue. IMMATICS herewith acknowledges that SANQUIN may in the course of performing
activities for its own account, subsequently and independently generate data, results or technology which are identical to data, results or technology included in or constituting Immatics Improvements. In such cases, if the use of such data, results
or technology would infringe a Valid Claim of an Immatics Improvement Patent, in partial consideration for the rights and license granted by SANQUIN to IMMATICS, IMMATICS undertakes not to file a lawsuit against SANQUIN for such use
(“Covenant Not To Sue”), provided that (i) SANQUIN sufficiently demonstrates to IMMATICS by written records maintained by SANQUIN in a systematic manner consistent with good scientific practices, that it independently generated
such data, results or technology without the use of, or reference to, any Confidential Information of IMMATICS or otherwise in relation to this Agreement and (ii) that such Covenant Not To Sue covers the use of the respective data, results or
technology only by SANQUIN (including its directors, officers and employees) and only in SANQUIN’s own premises (including for the performance of immunomonitoral services by SANQUIN for Third Parties) but not the use by Third Parties, and does
not cover the grant by SANQUIN of a license to Third Parties (including customers of SANQUIN). 

  

	3.4.	 License Option to Improvement Patents. IMMATICS grants SANQUIN the option to negotiate the grant of a non-exclusive, sublicensable, royalty-bearing license under IMMATICS’ rights in Immatics Improvement Patents to use the Immatics Improvements in a scope to be agreed by the Parties. Likewise, SANQUIN grants
IMMATICS the option to negotiate the grant of a non-exclusive, sublicensable, royalty-bearing, license under SANQUIN’s rights in Sanquin Improvement Patents to use the Sanquin Improvement Patents in a
scope to be agreed by the Parties and if no agreement can be reached in the same scope as the license granted pursuant to Section 2.1 (that is, to use the Sanquin Improvement Patents in the Field in the Territory). The exercise of the option
shall be made in writing. If and as soon as a Party has exercised the option in writing, the Parties shall enter into good faith negotiations. If such negotiations do not lead to agreement on the financial terms of such license within 60 (sixty)
days, the Parties shall submit the matter to an independent expert in the field to be appointed by the Parties jointly or, in absence thereof, by the chair of the Chamber of Commerce in Amsterdam out of a shortlist containing 4 experts (two
nominated by each Party) which expert will render a binding decision as to the consideration payable (taking into account the relative value of such Improvement and Improvement Patent(s) versus the value of the Sanquin Patent Rights) and the Parties
shall accept the binding decision of such expert. The costs of the expert shall be shared between the Parties. If the Parties cannot agree on the scope of the license under the Immatics Improvement Patents, Section 11.2 shall apply.

  

							
	License Agreement	    		  	 Page
 7
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	4.	 FEES AND PAYMENT 

 

	4.1.	 [***] In consideration of the license granted by SANQUIN to IMMATICS hereunder, IMMATICS shall pay to SANQUIN
[***]. 

  

	4.2.	 [***] in consideration of the license granted by SANQUIN to IMMATICS hereunder, subject to Section 4.5,
IMMATICS shall pay to SANQUIN [***], provided IMMATICS has received from SANQUIN a valid invoice [***] payable within thirty (30) days from receipt of such invoice. [***]. 

 

	4.3.	 [***] Subject to Section 4.5, the License Fee will, starting in 2016, increase every year [***] until a
maximum License Fee of [***]. 

  

	4.4.	 Service Fee. If IMMATICS performs activities for a Third Party on a fee-for-service base, making use of the Sanquin Patent Rights, subject to Section 4.5, IMMATICS will pay SANQUIN [***] invoiced by IMMATICS to the Third Party, after deduction from such fees invoiced to
the Third Party of any taxes (including VAT and withholding taxes) imposed on IMMATICS or payable by IMMATICS regarding such services fees. IMMATICS shall inform SANQUIN within 60 (sixty) days following the dispatch of the invoice to the Third Party
of the service fee invoiced to the Third Party and the Service Fee shall be payable within thirty (30) days from receipt by IMMATICS from SANQUIN of a valid invoice for the Service Fee. 

 

	4.5.	 Condition Precedent for Fees. Condition precedent for [***] shall be that the IP Status is as set forth
in Schedule 1. In the event that the IP Status changes by any of the below factors, IMMATICS shall have the right to request the adjustment of [***] in an amount/ percentage taking account of the decrease of the value of the Sanquin Patent Rights as
reasonably determined in good faith by the Parties jointly, taking into account the relevance of the respective Sanquin Patent Rights and the relevance of the respective affected territory for the business of IMMATICS. The factors under which [***]
be decreased shall be the following: 

  

	 	a.	 Rejection by the competent board of grant of Sanquin Patent Right 2 in Europe; 

 

	 	b.	 Rejection by the competent board of grant of Sanquin Patent Right 2 in the US; 

 

	 	c.	 One or more patents or patent applications included in the Sanquin Patent Rights in one or more Major European
Countries and/ or the US being held invalid or held unenforceable by a decision of a court from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal; 

 

	 	d.	 If a Third Party infringes any of the Sanquin Patent Rights and SANQUIN within forty-five (45) days after
the receipt of the notice from IMMATICS or having made the notice to IMMATICS (or should have made in the event of omission) in accordance with Section 3.2 does not take any action against the infringer, during the period that SANQUIN does not
take any action against the infringer, provided that the adjustment [***] an amount to reflect that the situation with respect to the Third Party infringer is equivalent to a licensee having a royalty-free, fully
paid-up license. 

  

							
	License Agreement	    		  	 Page
 8
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	4.6.	 Records. IMMATICS shall keep accurate and correct records of all service fees received from Third
Parties under this Agreement for which Service Fees to SANQUIN are due pursuant to Section 4.4. Such records shall be retained by IMMATICS for at least five (5) years. 

 

	4.7.	 Audit. IMMATICS shall make available to SANQUIN or a Third Party designated by SANQUIN and reasonably
acceptable to IMMATICS which Third Party is bound to confidentiality obligations customary for those types of audit but at least as strict as the confidentiality obligations under this Agreement, once per calendar year with at least four
(4) months prior notice during normal business hours such records of IMMATICS for inspection at the expense of SANQUIN which are necessary for the sole purpose of verifying payments by IMMATICS to SANQUIN. In the event that any such inspection
shows an underpayment in excess of five per cent (5%) for any twelve-month (12-month) period, then IMMATICS shall pay the reasonable cost of the audit as well as the difference between the actual payment made
and the payment that would have been payable to SANQUIN had IMMATICS reported correctly within thirty (30) days from receipt of a respective invoice from SANQUIN. For underpayment not in excess of five per cent (5%) for any twelve-month (12-month) period, IMMATICS shall pay the difference between the actual payment made and the payment that would have been payable to SANQUIN had IMMATICS reported correctly within thirty (30) days from receipt
of a respective invoice from SANQUIN, but without payment of SANQUIN’s inspection cost. Any documents reviewed and information disclosed by IMMATICS to SANQUIN or the Third Party auditor designated by SANQUIN in the course of such audit shall
be deemed to be Confidential Information of IMMATICS (whether marked as such or not) and shall be subject to the provisions set forth in Article 6. 

  

	4.8.	 Invoice Details. All invoices of SANQUIN to be sent to IMMATICS under this Agreement shall be sent to
the following address of IMMATICS or to any other address as notified by IMMATICS to SANQUIN in writing: 

  

	 	Immatics	 Biotechnologies GmbH 

 

	 	Paul-Ehrlich-Straße	 15 

  

	 	72076	 Tübingen, Germany 

 

	 	[***]	 

  

							
	License Agreement	    		  	 Page
 9
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	 	and	 each invoice shall include the following details: 

 

	 	-	 Name and address of SANQUIN 

 

	 	-	 Name and address of IMMATICS 

 

	 	-	 Date of invoice 

  

	 	-	 Number of Invoice 

  

	 	-	 Invoiced services, amount due and currency 

 

	 	-	 Amount of VAT due, if any 

 

	 	-	 VAT Identification Number or Tax Number of SANQUIN 

 

	4.9.	 Payment Details. All payments to be made under this Agreement by IMMATICS to SANQUIN shall be made to
the following account of SANQUIN or to any other account as notified by SANQUIN to IMMATICS in writing: 

  

	 	[***]	 

  

	4.10.	 Late Payment. All payments which are overdue under this Agreement will bear interest at a rate of [***]
from the date due through the date of payment. 

  

	4.11.	 Taxes. All payments mentioned in this Article 4 shall be exclusive of VAT, which shall be payable by
IMMATICS in addition, provided IMMATICS receives a respective proper invoice from SANQUIN, if applicable. 

  

	5.	 TERM AND TERMINATION 

 

	5.1.	 Term. This Agreement enters into force on the Effective Date and shall continue in full force and effect
until (i) expiry of the last Valid Claim included in the SANQUIN Patent Rights in the Territory, (ii) fifteen (15) years from the Effective Date, or (iii) termination in accordance with this Article 5, whichever will be the earliest
(collectively the “Term”). 

  

	5.2.	 Termination by Both Parties. This Agreement may be terminated: 

 

	 	a)	 Upon mutual written agreement between the Parties; 

 

	 	b)	 With immediate effect by each Party on written notice in the event of a material breach of the other Party
under this Agreement which breach the breaching Party has failed to remedy (if capable of remedy) within thirty (30) days of being given written notice thereof by the non-breaching Party;

  

							
	License Agreement	    		  	 Page
 10
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	 	c)	 With immediate effect by each Party on written notice in the event that the other Party is involved in any
legal proceedings concerning its insolvency, or ceases trading, or commits an act of bankruptcy or is adjudicated bankrupt or enters into liquidation, whether compulsory or voluntary, other than for the purposes of an amalgamation or reconstruction,
or makes an arrangement with its creditors or petitions for an administration order or has a receiver or manager appointed over all or any part of its assets or generally becomes unable to pay its debts. 

 

	5.3.	 Termination for Convenience. IMMATICS is entitled to terminate for convenience this Agreement at any
time with ninety (90) days notice after the [***]. 

  

	5.4.	 Termination by IMMATICS. Notwithstanding Section 5.3, IMMATICS is entitled to terminate this
Agreement at any time with immediate effect in the following situations: 

  

	 	a)	 If SANQUIN abandons in one or more Major European Countries or the US, whether by non-payment of fees or otherwise, any of the Sanquin Patent Rights 1 and/ or any of the Sanquin Patent Rights 2; 

  

	 	b)	 Subject to 5.4 c) below, if an Affiliate of SANQUIN or a Third Party files a lawsuit against IMMATICS within a
Major European Country or the US alleging that the use of the technology claimed in the Sanquin Patent Rights as such infringes the intellectual property rights of such Affiliate or Third Party and such lawsuit has not been withdrawn or settled
within 6 months after such lawsuit has been filed, provided, however, that this clause does not apply in the event that the exercise of the technology claimed in the Sanquin Patent Rights as such does not infringe any right of such Affiliate or a
Third Party but the monomers or multimers or fluorescent labels or other (whether or not biological) materials used by IMMATICS in applying the technology claimed in the Sanquin Patent Rights infringes the intellectual property rights of such
Affiliate or Third Party (as the use of such (biological or other) materials shall be at the sole risk and responsibility of IMMATICS); and 

  

	 	c)	 If a court of competent jurisdiction in a Major European Country or the US issues an order of cease and desist
or similar legal instrument against IMMATICS with respect to the use of the technology claimed in the Sanquin Patent Rights if such order of cease and desist or similar legal instrument is based on the (preliminary) decision of such court that the
use thereof by IMMATICS infringes the rights of an Affiliate of Sanquin or a Third Party. 

  

	5.5.	 Effects of Termination. Upon termination of this Agreement for any reason, IMMATICS shall immediately
return to SANQUIN or destroy all Confidential Information of SANQUIN and SANQUIN shall immediately return to IMMATICS or destroy all Confidential Information of IMMATICS, all as set forth in more detail under Section 6.4 and IMMATICS shall
immediately discontinue any use of the Sanquin Patent Rights, provided that the Parties shall agree on a reasonable, limited period (not to exceed 6 

  

							
	License Agreement	    		  	 Page
 11
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

	 	
months) of further use of the Sanquin Patent Rights after such termination solely for the purpose of and if such further use is necessary for IMMATICS to terminate any activities under any fee-for-service projects with Third Parties which activities have had already been started by the time notice of termination was given, provided IMMATICS undertakes reasonable
efforts to cancel the respective activities as soon as possible without incurring financial liability to the Third Party. The Parties shall agree on the survival of any licenses under Sanquin Improvement Patents or Immatics Improvement Patents, as
the case may be, granted pursuant to Section 3.4. 

  

	5.6.	 Survival. In addition to the termination consequences set forth in Section 5.5 (Effects of
Termination), the following provisions will survive termination or expiration of this Agreement: this Section 5.6, Article 6, Articles 7-9, Section 10.3, and Article 11. 

 

	5.7.	 Accrued Obligations. Termination or expiration of this Agreement will not relieve the Parties of any
liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of
this Agreement which occurred prior to the effective date of such termination or expiration nor prejudice either Party’s right to obtain performance of any obligation which was due prior to the effective date of such termination or expiration.
All other rights and obligations will terminate upon termination or expiration of this Agreement, except as set forth in Section 5.6. 

  

	6.	 CONFIDENTIALITY 

 

	6.1.	 Confidentiality Obligation. With respect to any and all Confidential Information received from the other
Party in the course of this Agreement, the Receiving Party shall: 

  

	 	a)	 keep such information confidential; 

 

	 	b)	 not communicate, disclose or otherwise make available such information to any Third Party except with prior,
written and explicit consent from the Disclosing Party; 

  

	 	c)	 communicate, disclose or otherwise make available such information to members of its personnel and those of its
Affiliates only and strictly on a “need-to-know” basis, that is, only in so far as disclosure to a particular individual is strictly necessary for the purpose
of this Agreement and always subject to confidentiality obligations no less stringent than those set out in this Article 6; 

  

	 	d)	 take all reasonable steps to ensure that such information shall be protected against unauthorized access,
theft, and the like. 

  

	6.2.	 Exemptions to Confidentiality. The obligations as set out in Section 6.1 shall not apply or shall
cease to apply, to information of which the Receiving Party can prove by (documentary) evidence: 

  

	 	a)	 that it was in the public domain prior to the disclosure under this Agreement; 

  

							
	License Agreement	    		  	 Page
 12
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	 	b)	 that it was in its possession prior to the disclosure under this Agreement, provided it was not acquired under
confidentiality obligations directly or indirectly from the Disclosing Party; 

  

	 	c)	 that, after its disclosure under this Agreement, it became part of the public domain by publication or
otherwise through no negligent or wilful act or omission of the Receiving Party; 

  

	 	d)	 that, after its disclosure under this Agreement, it was received by the Receiving Party from a Third Party who
did not acquire it directly or indirectly from the Disclosing Party, and who was legally entitled to disclose that information; 

  

	 	e)	 that it is required under a statutory duty and/or court order to disclose, provided that advance notice is
given to the Disclosing Party and the Receiving Party takes all reasonable measures to protect the confidentiality of the information; 

  

	 	f)	 that it was developed independently by the Receiving Party or its Affiliates without access to the Confidential
Information of the Disclosing Party. 

  

	6.3.	 Term of Confidentiality. The obligations of confidentiality and
non-use contained in Section 6.1 shall survive the termination of this Agreement for five (5) years. 

  

	6.4.	 Return or Destroy. Upon termination or expiration of this Agreement, each Party will at the first
request of the Disclosing Party return or destroy, at the election of the Disclosing Party, any and all of the Disclosing Party’s Confidential Information, except for one copy which the Receiving Party is entitled to keep in its archives for
the sole purpose of demonstrating compliance with this obligation. 

  

	6.5.	 Disclosure of Agreement. 

 

	 	a)	 Neither Party shall be entitled to issue a press release regarding this Agreement without the prior written
consent of the other Party, except for the press release attached in Schedule 2 on which the Parties have jointly agreed and the agreed language of which may also be used by each Party without the prior written consent of the other Party.

  

	 	b)	 Each Party is entitled to disclose the existence and general scope of this Agreement to its current and
potential business partners (including customers and investors). However, neither Party is entitled to disclose to any business partners or other Third Parties the contents (particularly the financials) of this Agreement without the prior written
consent of the other Party. 

  

							
	License Agreement	    		  	 Page
 13
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	7.	 REPRESENTATIONS AND WARRANTIES 

 

	7.1.	 Mutual Warranties. Each Party represents and warrants that: 

 

	 	a)	 it is duly organized and validly existing, with regard to SANQUIN under the laws of the Netherlands, and with
regard to IMMATICS under the laws of Germany, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 

  

	 	b)	 it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the
individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; and 

  

	 	c)	 this Agreement is legally binding upon it and enforceable in accordance with its terms; and the execution,
delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable law. 

 

	7.2.	 Sanquin Warranties. SANQUIN represents, warrants and covenants to IMMATICS that: 

 

	 	a)	 it has the lawful right and is lawfully entitled to grant this license in the scope as granted hereunder and
that the grant of the license hereunder does not conflict with any other contracts or agreements to which it is a party or with any other obligations of it and that the Sanquin Patent Rights are not encumbered with any right of pledge, usufruct,
seizure or other security, owner or exclusive license right of Affiliates or Third Parties; 

  

	 	b)	 As of the Effective Date the maintenance fees for all patents and patent applications included in the Sanquin
Patent Rights have been timely and properly paid; 

  

	 	c)	 SANQUIN has no knowledge that any Third Party has infringed or is currently infringing the Sanquin Patent
Rights, provided that SANQUIN is aware of the fact that the technologies are being used by academic institutions for research purposes only within the scope of use for research purposes which is by applicable patent laws considered not to be an
infringing act and that SANQUIN will inform IMMATICS in accordance with Section 3.2, in the event that it becomes aware of an infringement (for the avoidance of doubt, such information by SANQUIN to IMMATICS shall be made for any infringement,
not only substantial infringements as set forth in Section 3.2). 

  

	 	d)	 As of the Effective Date no opposition proceedings, nullity actions, invalidity actions or the like challenges
of the Sanquin Patent Rights are pending; nor has SANQUIN been notified or is otherwise aware of any threatened opposition proceedings, nullity actions, invalidity actions or the like challenges of the Sanquin Patent Rights; 

 

	 	e)	 As of the Effective Date the IP Status as described in Schedule 1 is correct; and in the event of any changes
of the IP Status as described in Schedule 1 SANQUIN will inform IMMATICS in writing within 15 Business Days after Sanquin becomes aware of a change of the IP Status; and 

 

	 	f)	 it is not aware of any circumstances that could lead to a substantial reduction of the claims under Sanquin
Patent Right 1 in the US and/ or Europe or could prevent the grant of Sanquin Patent Right 2 in the US and/ or Europe or could lead to a substantial reduction of the claims under Sanquin Patent Right 2 in the US and/ or Europe.

  

							
	License Agreement	    		  	 Page
 14
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	7.3.	 Limited Warranties. Save for the warranties under Section 7.2 hereof, SANQUIN makes no
representations and extends no warranties of any kind, either expressed or implied, in relation to the Sanquin Patent Rights, the uses thereof or their suitability for any particular purpose. 

 

	8.	 INDEMNIFICATION 

 

	8.1.	 Parties Indemnification. Each Party (“Indemnitor”) agrees to indemnify,
defend and hold harmless the other Party, its Affiliates, and their respective officers, directors and employees (collectively “Indemnitee”) from and against all claims, demands, liabilities, suits, damages, costs and expenses of
every kind and description, including penalties and reasonable attorneys fees, (collectively “Losses”), incurred, suffered by or imposed upon the Indemnitee to the extent resulting from any wilful misconduct or negligent act or
omission of the Indemnitor (including its officers, directors and employees), provided that such indemnity shall not apply to the extent that the Losses arise out of or result from the wilful misconduct or negligent act or omission by the Indemnitee
or its officers, directors or employees. 

  

	8.2.	 Additional Indemnification Immatics. Notwithstanding Section 8.1, IMMATICS shall and hereby agrees
to indemnify and hold harmless SANQUIN in full in respect of any Losses incurred or suffered by or imposed upon SANQUIN resulting from or in connection with (i) the use and/or the exploitation of the Sanquin Patent Rights by IMMATICS or (ii),
subject to (iii), from any negligent or wilful breach by IMMATICS of any of its obligations under this Agreement or (iii) from any breach by IMMATICS of any of its representations and warranties under Section 7.1, except to the extent that
such Losses are due to a breach of representations and warranties by SANQUIN pursuant to Section 7.1 or 7.2 or a negligent or wilful breach by SANQUIN of any of its obligations under this Agreement. 

 

	8.3.	 Additional Indemnification Sanquin. Notwithstanding Section 8.1, SANQUIN shall and hereby agrees to
indemnify and hold harmless IMMATICS in full in respect of any Losses incurred or suffered by or imposed upon IMMATICS resulting from (i), subject to (ii), any negligent or wilful breach by SANQUIN of any of its obligations under this Agreement, or
(ii) any breach by SANQUIN of any of its representations and warranties under Section 7.1 or 7.2, except to the extent that such Losses are due to a breach of the representations and warranties by IMMATICS pursuant to Section 7.1 or a
negligent or wilful breach by IMMATICS of any of its obligations under this Agreement. For the avoidance of doubt, subject to the more detailed provisions in Section 8.4, in the event that a Loss of IMMATICS results from the fact that SANQUIN
is not entitled to grant the license as 

  

							
	License Agreement	    		  	 Page
 15
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

	 	
granted hereunder, because the Sanquin Patent Rights are encumbered with rights of Affiliates of Sanquin or with Third Party rights, the indemnification by SANQUIN hereunder shall include that
SANQUIN is responsible for acquiring the respective rights and licenses at its expense and is solely responsible for any royalties or other fees payable by SANQUIN to such Affiliate or Third Party. 

 

	8.4.	 Indemnification Procedure. The Indemnitee shall provide prompt written notice to the Indemnitor of the
initiation of any action or proceeding that may reasonably lead to a claim for indemnification pursuant to Section 8.1, 8.2 or 8.3 and permit, to the extent permitted by applicable laws, the Indemnitor to take control of the defense of such
claims and any related settlement negotiations and cooperate and, at the Indemnitor ́s reasonable request and expense, assist the Indemnitor with the defense of such claims. To the extent legally permissible under the applicable laws, the
Indemnitee may, notwithstanding the Indemnitor ́s right to control the defense of a claim, at its option and own expense, select to participate in such claim and be represented by separate counsel of its own choosing. The Indemnitor may not
settle or compromise any claim without the prior written consent of the Indemnitee, such consent not to be unreasonably withheld or delayed. 

  

	9.	 LIMITATION OF LIABILITY 

 

	9.1.	 Exclusion of Indirect Damages. Save for gross negligence or wilful misconduct and any breach of the
representation and warranty set forth in Section7.2(a), SANQUIN shall in no event be liable to IMMATICS for any indirect or consequential loss, damage, claim, demand and/or expense of IMMATICS – of whatever nature – whether arising by way
of a Third Party claim or otherwise – resulting from or in connection with the use and/or the exploitation of the Sanquin Patent Rights by IMMATICS under this Agreement. Likewise, save for gross negligence or wilful misconduct, IMMATICS shall
in no event be liable to SANQUIN for any indirect or consequential loss, damage, claim, demand and/or expense of SANQUIN – of whatever nature – whether arising by way of a Third Party claim or otherwise under this Agreement.

  

	9.2.	 Limitation of Liability. The total annual liability of each Party under this Agreement shall never
exceed two (2) times the annual amount payable by IMMATICS to Sanquin in such annum under this Agreement. 

  

							
	License Agreement	    		  	 Page
 16
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	10.	 MISCELLANEOUS 

 

	10.1.	 Assignment. Neither Party may assign or transfer, in whole or in part, its rights or obligations under
this Agreement, without the other Party’s prior written consent, except that each Party may, however, assign or transfer this Agreement without the prior written consent of the other Party (a) to an Affiliate or (b) as part of the
sale, assignment or conveyance of all or substantially all of its business assets to which this Agreement relates to a Third Party or in the context of a merger, consolidation or restructuring provided that such Affiliate or Third Party assumes all
of the obligations of the assigning Party under this Agreement. In any event of allowed assignment, the assigning Party shall inform the other Party of such assignment within 10 Business Days after such assignment has been consummated.

  

	10.2.	 No Waiver. A waiver by a Party of a breach or default of the other Party under any of the provisions of
this Agreement shall not be construed as a waiver of any succeeding breach of the same or other provisions. Nor shall any delay or omission on the part of a Party to exercise or avail itself of any right, power or privilege that it has or may have
under this Agreement, operate as a waiver of any breach or default by the other Party. 

  

	10.3.	 Notices. Any notice or other communication under this Agreement shall be in writing and shall be
sufficiently served if sent personally or by international courier service or registered mail (postage prepaid) to the address; 

In the case of notices to SANQUIN to: 

Stichting SANQUIN Bloedvoorziening 

Plesmanlaan 125 
 1066 CX
Amsterdam 
 The Netherlands 

Attn: Business Development Manager of the Division Reagents 

With reference number: 
 In the
case of notices to IMMATICS: 
 Immatics Biotechnologies GmbH 

Paul-Ehrlich-Strasse 15 
 72076
Tuebingen 
 Germany 
 Attn:
Managing Director 
 With reference number: 
  

	10.4.	 Entire Agreement. This Agreement contains the entire agreement of the Parties in relation to its subject
matter. Any Schedules to this Agreement shall form a part thereof. This Agreement may only be amended or supplemented in writing, by way of a document signed by (the authorised representatives of) the Parties. 

  

							
	License Agreement	    		  	 Page
 17
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

  

	10.5.	 Invalidity. If part of this Agreement is or becomes invalid or unenforceable, the Parties shall remain
bound to the remaining part. The Parties shall replace the invalid or unenforceable part by provisions which are valid and binding and the effect of which, given the contents and purpose of this Agreement, is, to the greatest extent possible,
similar to that of the invalid or unenforceable part. 

  

	11.	 GOVERNING LAW AND DISPUTE RESOLUTION 

 

	11.1.	 Governing Law. This Agreement shall be governed and construed in accordance with the substantive laws of
the Netherlands without regard to the conflict of laws provisions thereof. 

  

	11.2.	 Dispute Resolution. In the event of any disputes arising out of or in connection with this Agreement,
including disputes concerning the existence and validity thereof, the Parties shall first make reasonable efforts to settle the dispute between themselves and shall to this end refer the dispute to a general manager of each Party as named by each
Party. The general managers to whom such dispute is submitted shall attempt to resolve the dispute through good faith negotiations within thirty (30) days from submission unless the Parties agree otherwise. If the general managers are unable to
resolve the dispute within the determined time, the dispute shall be finally settled by binding arbitration in accordance with the Arbitration Rules of the International Chamber of Commerce (“ICC”). The arbitral tribunal shall consist of
three members (one chairman and two associates), unless agreed otherwise. The chairman shall have undergone a qualification as a lawyer or jurist and the associates shall possess significant experience in the pharmaceutical and biotechnology
industry. Place of arbitration shall be Amsterdam, The Netherlands. The language of the arbitration proceedings shall be English, unless agreed otherwise. 

  

							
	License Agreement	    		  	 Page
 18
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

 The Parties have executed this Agreement as follows: 

STICHTING SANQUIN BLOEDVOORZIENING 
  

					
	/s/ Jeroen de Wit	  		  	
			
	Name: Jeroen de Wit	  		  	
	 Title: Vice Chairman Executive Board

Sanquin Blood Supply Foundation
	  		  	

 IMMATICS BIOTECHNOLOGIES GMBH 
  

					
	/s/ Rainer Kramer	  		 	/s/ Harpreet Singh
			
	Name: Dr. Rainer Kramer	  		 	Dr. Harpreet Singh
	Title: Managing Director/CBO	  		 	Managing Director/CSO

  

							
	License Agreement	    		  	 Page
 19
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

 Schedule 1 

IP Status 
 [***] 

  

							
	License Agreement	    		  	 Page
 20
 of 21
				
	Sanquin	  	 	    	Immatics	  	 

 License Agreement 

Execution Copy, Immatics August 3rd 2015 
  

 Schedule 2 

Press Release 
 Concept of text to be
used freely by Immatics and Sanquin in external outings 
 Sanquin licenses its MHC IP portfolio to Immatics to support the development of
onco-immunotherapies. 
 Sanquin Blood Supply Foundation (Amsterdam, The Netherlands) has granted Immatics Biotechnologies GmbH (Tuebingen, Germany) a non-exclusive license to use its proprietary MHC T cell technologies to advance the development of immunotherapies in the field of oncology and infectious diseases. 

Cytotoxic T cells in patients can kill cancerous and infected cells when their T Cell Receptor (TCR) recognizes disease specific peptides (antigens) presented
by so-called major histocompatibility complex (MHC) on the infected/ tumor cell. The technologies licensed to Immatics enable fast and simple generation of large series of
peptide-MHC complexes for in vitro immunogenicity assays and for detecting the corresponding antigen-specific T cells in patient samples. 

  

							
	License Agreement	    		  	 Page
 21
 of 21
				
	Sanquin	  	 	    	ImmaticsEX-10.10

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Exhibit 10.10 
 Execution Copy 

FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT 

THIS FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT (“Agreement”), dated effective as of September 1, 2015
(“Effective Date”), is made and entered into by and between The University of Texas Health Science Center at Houston (“UTHealth”), an institution of The University of Texas System and governed by the Board of
Regents (“Board”) and Immatics US, Inc., a Delaware corporation (“Immatics”). 
 WHEREAS, UTHealth
operates a United States Food and Drug Administration (“FDA”) registered facility for manufacturing of human cells in compliance with current Good Manufacturing Practice (cGMP), namely UTHealth - Medical School, The Evelyn H. Griffin Stem
Cell Therapeutics Research Laboratory, FDA Establishment Identifier 3009561521, located at 1941 East Rd., Houston, Texas 77054-6010 (“Facility”) and including certain equipment which can be used for the manufacture of therapeutic T Cells;
and 
 WHEREAS, Immatics and The University of Texas MD Anderson Cancer Center (“Authorized Collaborator”) are collaborating on
the ACTolog and ACTengine clinical trials requiring the use of therapeutic T Cells (collectively “Projects”); and 
 WHEREAS,
Immatics is interested in contracting with UTHealth to make its Facility, certain equipment, and personnel available to manufacture therapeutic T Cells in support of the Projects. 

NOW, THEREFORE, in consideration of the foregoing, the provisions contained herein and the mutual benefits to be derived herefrom, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
  

	1.	 Licensed Facilities; Licensed Equipment; Permitted Use; and Services. 

 

	 	1.1	 Licensed Facilities. Subject to the terms and conditions of this Agreement, UTHealth grants to Immatics
and its employees, agents, and Authorized Collaborator, and Immatics accepts from UTHealth: 

  

	 	a	 Production Suites/Administrative Space. An exclusive license to use certain production suites and
administrative space located in the Facility, described as Rooms BBS 6310, BBS 6312, and a cubicle in BBS 6102 (the “Premises”). The use of Room BBS 6310 shall be for the period September 1, 2015 through December 31, 2017 and the
use of Room BBS 6312 shall be for the period March 1, 2016 through December 31, 2018. 

  

	 	b	 Common Areas. A non-exclusive license to use the common areas of
the Facility, related improvements, and the land where the Facility is situated described as storage rooms (BBS 1408 and 6100), autoclave room (BBS 5120), Main Entry/Exit Room (BBS 6318), Changing Room (BBS 63I8A), Sterile Gowning Room (BBS 6308), De-Gowning Room BBS 6318B), Clean Storage Room (BBS 6308A), Quarantine Room (BBS 6302), Released Supply Room (BBS 6304), Bulk Materials Pass-Through Room

  
  

Page 1 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

	 	
(BBS 6306), entry and exit hallways (BBS 6306A and 6318C), Labeling Room (BBS 6102B), and any other rooms as reasonably required to make effective use of the Premises (collectively the
“Common Areas”). 

 The Premises, and Common Areas are collectively referred to herein as the
“Licensed Facilities.” 
  

	 	1.2	 Permitted Days and Times. The licenses herein granted shall be for use of the Licensed Facilities by
Immatics as follows: 

 Monday through Friday 7:00am to 7:00pm, excluding UTHealth holidays unless prior approval is
received from Facility Director. 
  

	 	1.3	 Permitted Use. Immatics shall use the Licensed Facilities solely for the purpose of manufacturing
therapeutic T Cells and related developmental and administrative activities in support of the Projects, and in accordance with the provisions of this Agreement. In using the Licensed Facilities, Immatics shall comply with the Facility’s Quality
Management System and with all applicable federal, state and local statutes, rules, regulations, codes, ordinances and policies and applicable UTHealth rules, regulations, policies, and procedures. 

 

	 	1.4	 UTHealh Representations. UTHealth represents that i) it is in possession of all authorizations required
to maintain the Facility as a cGMP-approved facility and that there is no reason to believe that any such authorization will be revoked or withdrawn; and ii) it conforms with all applicable laws, regulations, rules, and guidelines commonly accepted
for a facility of this kind. 

  

	 	1.5	 Licensed Equipment. Subject to the terms and conditions of this Agreement, UTHealth grants to Immatics,
and Immatics accepts from UTHealth a license to use certain equipment owned by UTHealth in support of the Projects as referenced in Section 1.3 above. The items of Equipment are more particularly described on Exhibit A
(“UTHealth Equipment”). 

 Immatics shall be allowed to purchase and install the equipment set forth in
Exhibit B (“Immatics Equipment”) in the Licensed Facilities upon written approval from UTHealth, which will not be unreasonably withheld. All such Immatics Equipment must meet UTHealth
specifications and otherwise comply with all federal and state laws and regulatory requirements. Modifications to Immatics Equipment and/or installation of additional Immatics equipment will need approval of the Facility Director and any related
budgetary changes will be incorporated into an Amendment to the Agreement. 
 UTHealth shall be responsible for maintaining the University
Equipment and the Immatics Equipment listed on Exhibit B. 

  
  

Page 2 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

 Upon termination of this Agreement, and if agreed to by Immatics, UTHealth shall have the
option to purchase Immatics Equipment installed in the Licensed Facilities at the current fair market value. 
  

	2.	 Condition of Licensed Facilities and UTHealth Equipment. 

 

	 	2.1	 Preservation. Immatics shall not, without the prior approval of UTHealth, cause or allow to be caused
any activity whereby the Licensed Facilities or any UTHealth Equipment or property owned or operated by UTHealth are damaged, marred or defaced. 

  

	 	2.2	 Alterations. Immatics shall not make any alterations to the Licensed Facilities or UTHealth Equipment.
Any alterations to Immatics Equipment installed in the Licensed Facilities must be approved by UTHealth, such approval not to be unreasonably withheld. 

  

	 	2.3	 Damage. Immatics shall return the Licensed Facilities to UTHealth after the Term in the same condition
as when received, excepting only normal wear and tear, and Immatics shall reimburse UTHealth upon demand for any and all costs, expenses, charges or fees incurred in the repair or replacement of damage to the Licensed Facilities and UTHealth
Equipment as a result of the acts or omissions of Immatics, its employees, agents, or Authorized Collaborator. 

  

	 	2.4	 Materials. Immatics shall not bring, place, store, or use on or about the Facility any materials,
including, but not limited to asbestos containing materials, petroleum, explosives, toxic, reactive, corrosive, biohazardous, or radioactive materials, medical wastes, substances defined as hazardous wastes, hazardous materials, or hazardous
substances under or regulated by any federal, state, or local law, rule, order or regulation, or any inflammable materials or odorous solvents or materials without the prior approval of UTHealth, which approval will not be unreasonably withheld.

  

	3.	 Personnel, Consumable Supplies, and Services. 

 

	 	3.1	 Personnel. Manufacturing of Immatics products will be the primary responsibility of Immatics personnel.
However, at the discretion of the Facility Director, UTHealth may make employees available (on a temporary as-needed basis) to assist Immatics in manufacturing T Cells in accordance to the processes set forth
in Exhibit C (“Manufacturing Program”). Such processes may be adjusted, as necessary, without a formal amendment upon the written approval of the Director of the Facility or his/her designee and Immatics.

  

	 	3.2	 QA/QC. UTHealth personnel shall provide quality assurance and quality control activities to maintain
facility compliance in support of the immatics products. All procedures and processes including QC assays performed for product release and corresponding documentation (e.g., SOPs, validations) will require review and approval by Facility’s
Quality team and product may not be released unless both 

  
  

Page 3 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

	 	
Immatics and Facility Quality teams approve and sign the release. Complete manufacturing documentation for each batch (e.g., batch records, QC result reports, manufacturing SOPs) will be stored
in the Facility’s archive to ensure compliance with current regulations and the Facility’s Quality Management System. 

  

	 	3.3	 Consumable Supplies and Service. UTHealth shall make available the consumable supplies and services set
forth in Exhibit D for use in the Manufacturing Program. Process-specific reagents and supplies are not included in the cost set forth in Exhibit D and shall be invoiced separately. Reagents and supplies for cGMP
manufacture will be purchased from vendors qualified by the Facility. 

  

	4.	 HIPAA. UTHealth and Immatics shall comply with all applicable laws, rules, regulations and policies
related to the privacy and confidentiality of health information, including “protected health information” as defined under the federal “Administrative Simplification Provisions” of the Health Insurance Portability and
Accountability Act of 1996, and as provided under the Texas Health and Safety Code and other applicable state and local laws, as the foregoing may be amended from time to time. 

 

	5.	 Term. 

  

	 	5.1	 This Agreement shall commence as of September 1, 2015, and shall continue until December 31, 2018
(“Term”), unless the term is otherwise limited as set forth in Section 1.1a or Section 5.2. 

  

	 	5.2	 Immatics may terminate this Agreement upon sixty (60) days prior written notice, provided that Immatics
has identified another entity that is willing and able to utilize the Premises for the then-remaining balance of the Term on economic terms at least as favorable to UTHealth as those set forth in this Agreement, subject to UTHealth’s consent to
such entity, which consent shall not be unreasonably withheld, delayed or conditioned. 

  

	6.	 Liability and Insurance. 

 

	 	6.1	 Indemnification. 

 

	 	a	 Immatics shall be fully liable for and hold harmless and indemnify UTHealth from any and all demands, claims,
suits, damages, losses, liabilities, costs and expenses of any nature whatsoever (including, but not limited to, property damage and loss, bodily injuries, sickness, disease or death)(collectively, “Claims”), directly or indirectly arising
out of or in connection with Immatics’s and Authorized Collaborator’s use of the Licensed Facilities, except to the extent arising in connection with UTHealth’s breach of this Agreement or negligence, gross negligence or willful
misconduct. 

  

	 	b	 UTHealth, to the extent permitted by law, shall be fully liable for and hold harmless and indemnify Immatics
from any and all Claims to the extent arising in connection with UTHealth’s breach of this Agreement or negligence, gross negligence or willful misconduct. 

  
  

Page 4 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

  

	 	c	 The indemnified party shall promptly notify the indemnifying party in writing of any Claim for which it intends
to seek indemnification hereunder and cooperate reasonably with the indemnifying party at the indemnifying party’s sole cost and expense. The indemnifying party shall have the right, within thirty (30) days after being so notified, to
assume the defense of any Claim with counsel of its choice that is reasonably satisfactory to the indemnified party. The indemnifying party shall not settle any Claim in a manner that adversely affects the rights of the indemnified party without the
indemnified party’s prior written consent, which consent shall not be unreasonably withheld or delayed. The indemnified party’s failure to provide prompt notice to the indemnifying party of any Claim shall not relieve the indemnifying
party of its obligations under this Section 6.1 except to the extent that the indemnifying party can demonstrate that it has been materially prejudiced as a result of the failure. The indemnified party may participate in and observe the
proceedings at its own cost and expense with counsel of its own choosing, subject to the indemnifying party’s right to control the defense and settlement thereof. Notwithstanding anything to the contrary contained herein, Immatics’s right
to assume the defense of a Claim involving UTHealth is subject to the Texas Attorney General’s constitutional/statutory duty to represent UTHealth. 

  

	 	d	 The provisions of this Section 6.1 shall survive the expiration or earlier termination of this Agreement.

  

	 	6.2	 Insurance. 

  

	 	a	 Immatics shall procure and maintain, at Immatics’s sole cost and expense, the following insurance coverage
for Immatics’s use of the Licensed Facilities. Immatics represents and warrants that such insurance shall cover Authorized Collaborator’s activities conducted in the Licensed Facilities pursuant to this Agreement: 

 

	 	(i)	 Property Insurance. Property insurance for its property in the Licensed Facilities.

  

	 	(ii)	 Workers’ Compensation Insurance. Workers’ Compensation Insurance with statutory limits, and
Employers Liability Insurance with minimum coverage limits of not less than [***]: 

 [***] Employers Liability - Each
Accident 
 [***]Employers Liability - Each Employee 

[***]Employers Liability - Policy Limit 

  
  

Page 5 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

 This policy shall include a waiver of subrogation in favor of UTHealth. 

 

	 	(iii)	 Commercial General Liability Insurance. Commercial General Liability Insurance (occurrence basis) with
the following minimum coverage limits: 

 Each Occurrence
Limit                                        
        [***] 
 Damage to Licensed
Facilities                                     [***] 

Medical Expense (any one
person)                              [***] 

Personal & Advertising
Injury                                     [***] 

General
Aggregate                                        
               [***] 
 This policy shall be on a form reasonably
acceptable to UTHealth, endorsed to include UTHealth as an additional insured and contain no modification that would make Immatics’s policy excess or contributory with any UTHealth liability insurance. 

 

	 	(iv)	 Umbrella Excess Liability Insurance. Umbrella Excess Liability Insurance with minimum coverage limits
of: 

 Bodily
Injury!                                 [***]per occurrence 

Property
Damage                            [***]aggregate 

(Occurrence Basis) 
 This policy
shall be written on a following form umbrella excess basis above the Worker’s Compensation and Commercial General Liability coverages described above, and shall be endorsed to include UTHealth as an additional insured. 

 

	 	(v)	 Immatics shall furnish UTHealth with evidence of the insurance policies required under this Section 6.2 a.
prior to the beginning of the first use of the Licensed Facilities, and thereafter to furnish UTHealth with copies of renewal policies at least fifteen (15) days before the expiration of any policies. 

 

	7.	 Intellectual Property. a) Inventorship shall be determined by U.S. Patent law. Title to all inventions
and discoveries made or conceived and reduced to practice solely by UTHealth or UTHealth employees during the Term and resulting directly from the performance of this Agreement shall reside in Board on behalf of UTHealth (“University
Inventions”); title to all inventions and discoveries made or conceived and reduced to practice solely by Immatics or Immatics employees during the Term of this Agreement and resulting directly from the performance of this Agreement shall
reside in Immatics (“Immatics Inventions”); title to all inventions and discoveries made or conceived and reduced to practice jointly by UTHealth employees and Immatics employees during the Term of this Agreement and resulting directly
from the performance of the this Agreement shall reside jointly in Board on behalf of UTHealth and Immatics (“Joint Inventions”). No intellectual property of any 

  
  

Page 6 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

	 	
party either outside of this Agreement and/or created before the Effective Date shall be conveyed under this Agreement. Any rights to inventions and discoveries made or conceived and reduced in
whole or in part by employees of The University of Texas M.D. Anderson Cancer Center shall not be conveyed under and are not represented by this Agreement. 

For University Inventions and Joint Inventions that specifically and only apply to the manufacturing of Immatics
T-cells contemplated under this Agreement (“Immatics Program Specific T-Cell Inventions”), UTHealth will promptly and confidentially disclose to Immatics any
Immatics Program Specific T-Cell Inventions resulting directly from the Manufacturing Program after creation and reduction to practice, and after Principal Investigator’s disclosure to University’s
Office of Technology Management (“OTM”). The disclosure to Immatics shall be in the form of a written report and shall identify the inventor(s) and the Agreement under which the Immatics Program Specific
T-Cell Inventions was made. Immatics shall retain all reports and invention disclosures submitted to Immatics by the University as Confidential Information per the terms of Section 8. Immatics will notify
OTM within sixty (60) days of receipt of such disclosure whether: i. Immatics desires University to file patent applications on any such Immatics Program Specific T-Cell Inventions, in which case Immatics
shall reimburse all University patent application filing costs, including costs for patentability opinions in connection therewith; or ii. Immatics requests to use its own patent counsel to file patent applications on such Immatics Program Specific T-Cell Inventions, in which case Immatics shall obtain University prior written approval of counsel and of patent application, not to be unreasonably withheld, and provided that such patent counsel enters into an
appropriate contract and joint representation waiver with Board and copies OTM on all patent documentation and correspondence; in such instance, Immatics shall be directly responsible for all such patent expenses in connection therewith; or iii.

 Immatics does not desire to support a patent application on such Immatics Program Specific T-Cell
Inventions, in which case Board’s rights to such Immatics Program Specific T-Cell Inventions shall be disposed of in accordance with University policies with no further rights or obligations to Immatics.

 b) Option to Immatics. With respect to Immatics Program Specific T-Cell Inventions for which
Immatics has agreed to file patent applications or to reimburse University’s costs for filing patent applications under 7(i) or 7(ii) above, Board grants to Immatics, subject to the following terms, an exclusive option to negotiate, at the
choice of Immatics, either an exclusive or non- exclusive, worldwide, royalty-bearing license to make, use or sell a commercial product under any Immatics Program Specific
T-Cell Inventions. Immatics shall have three (3) months from disclosure of any Immatics Program Specific T-Cell Inventions (“Option Period”) to notify
University of its desire to enter into such a license agreement, and the parties shall negotiate in good faith for a period not to exceed three (3) months after such notification (“Negotiation Period”), or such period of time as to
which the parties shall mutually agree in writing. Business terms in any such license shall take into account, among other factors, terms and conditions customary to University’s typical commercial license agreements. If Immatics does not
provide University timely notice during the Option Period and/or Immatics and University fail to enter into an 

  
  

Page 7 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

 
agreement during the Negotiation Period, Board’s rights to such Immatics Program Specific T-Cell Inventions shall be disposed of in accordance with
University policies with no further rights or obligations to Immatics. 
  

	8.	 Confidential Information. The parties may wish to disclose certain information to each other in
connection with the activities contemplated under this Agreement (“Confidential Information”). Each party will only use Confidential Information to fulfill the purpose of this Agreement and shall use reasonable efforts to prevent the
disclosure of the other party’s Confidential Information to third parties for a period of five (5) years from termination or expiration of this Agreement, provided that the recipient party’s obligation shall not apply to information
that: 

  

	 	a)	 is not disclosed in writing or reduced to writing and marked with an appropriate confidentiality legend within
thirty (30) days after disclosure; 

  

	 	b)	 is already in the recipient party’s possession at the time of disclosure; 

 

	 	c)	 is or later becomes part of the public domain through no fault of the recipient party; 

 

	 	d)	 is received from a third party having no obligation of confidentiality to the disclosing party;

  

	 	e)	 is independently developed by the recipient party; or 

 

	 	f)	 is required by law or regulation to be disclosed. 

In the event that information is required to be disclosed pursuant to subsection f), the party required to make disclosure shall promptly
notify the disclosing party to allow that party to assert whatever exception or exemptions may be available to it under such law or regulation. 
  

	9.	 Compensation. In consideration for the license herein granted for the use of the Licensed Facilities and
the other services provided by UTHealth pursuant to this Agreement, Immatics shall compensate UTHealth as follows: 

  

	 	•	 	 A one-time comprehensive fee of [***] in accordance with the budget set
forth in Exhibit E-1 

  

	 	•	 	 a base monthly fee of [***] per production suite (i.e., BBS 6310 and/or 6312) calculated in accordance with the
budget set forth in Exhibit E-2 for the applicable term set forth in section 1.1a; 

  

	 	•	 	 a per patient fee for [***] ACTolog project in the amount of [***] calculated in accordance with the budget set
forth in Exhibit E-3; and 

  

	 	•	 	 a per patient fee for [***] ACTengine project in the amount of [***] calculated in accordance with the budget set
forth in Exhibit E-3. 

  
  

Page 8 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

 Process specific reagents and other supplies are not included in the cost set forth above and
shall be invoiced to Immatics as a separate line item charge. 
 All payments shall be made within thirty (30) days after receipt of the
invoice and mailed to the address below or sent by electronic funds transfer: 
 The University of Texas Health Science Center at Houston

 6431 Fannin Street, MSB 5.226 

Houston, TX 77030 
 Attn: Diane
Harnden 
  

	10.	 Notices. All notices, claims, requests for approval, demands, or other communications provided for or
permitted to be given under any of the provisions of this Agreement shall be in writing and shall be deemed to have been duly given or served when delivered by hand delivery, mailed by first-class, registered or certified mail, or faxed with
appropriate confirmation, as set forth below: 

  

			
	Notice to UTHealth:	  	Notice to Immatics:
		
	The University of Texas Health	  	Immatics US, Inc.
	Science Center at Houston	  	700 Milam Street, Suite 1300
	6431 Fannin Street, MSB 5.226	  	Houston, TX 77002
	Houston, TX 77030	  	Attn: Dr. Steffen Walter
	Attn: Diane Harnden	  	

  

	11.	 Miscellaneous. 

 

	 	11.1	 Entire Agreement: Severability. This Agreement constitutes the entire agreement between the parties, and
supersedes all prior and contemporaneous agreements, understandings and negotiations, with respect to the subject matter hereof. In the event any provision of this Agreement shall be held unenforceable by a court of competent jurisdiction, such
unenforceability shall not affect any other provision hereof, and this Agreement shall be construed as if such unenforceable provision, to the extent of such unenforceability, had not been incorporated herein. 

 

	 	11.2	 Use of Names. No party will use the name, trademarks, or other marks of any other party without the
prior written consent of the party. 

  

	 	11.3	 Independent Contractors. For the purposes of this Agreement, the parties shall be, and shall be deemed
to be, independent contractors and not agents or employees of the other parties. No party shall have authority to make any statements, representations, or commitments of any kind, or take any action which shall be binding on any other party, except
as may be expressly provided for herein or authorized in writing. 

  

	 	11.4	 Force Majeure. No party shall be liable to any other party for failure to perform and of its respective
obligations imposed by this Agreement if such failure shall be 

  
  

Page 9 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

 Execution Copy 
  

	 	
occasioned by fire, flood, explosion, lightning, windstorm, earthquake, subsidence of soil, governmental interference, civil commotion, riot, war, terrorism, strikes, labor disturbance, or any
other cause beyond its reasonable control. 

  

	 	11.5	 No Assignment; No Amendment. This Agreement (i) may not be assigned or transferred, in whole or in
part, by operation of law or otherwise, by either party without the prior written consent of the other party, except that a Party may assign this Agreement to a person or entity that acquires all or substantially all of its business or assets to
which the Agreement primarily relates; and (ii) may not be amended or modified except in a writing duly executed by each of the parties. 

  

	 	11.6	 Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the
laws of the State of Texas. 

  

	 	11.7	 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original,
but all of which taken together shall constitute one and the same instrument. 

 Signatures on Following Page 

  
  

Page 10 

 Execution Copy 
  

 EXECUTED on the date(s) set forth below, to be effective as of the date first written above.

  

									
	The University of Texas Health	 		 	Immatics US, Inc.
	Science Center at Houston	 		 		 	
			
	By: /s/ T. Kevin
Dillon                                	 		 	By: Steffen
Walter                                
	 Name: T. Kevin Dillon

Title:   Senior Executive Vice President

Chief Operating and Financial Officer
	 		 	 Name: Steffen Walter

Title:   CSO

			
	Date Signed: 8/31/15                    	 		 	Date Signed: 9/2/15                    
				
		 		 		 	Immatics US, Inc.
				
		 		 		 	By: /s/ Harpreet Singh                          
		 		 		 	 Name: Harpreet Singh

Title:   CEO

				
		 		 		 	Date Signed: 9/2/15                    

  
  

Page 11 

 Execution Copy 
  

 EXHIBIT A 

UTHealth Equipment in cGMP Production Suites 
  

			
	 UTHealth Equipment
	  	 Number per suite

	 [***]
	  	1
		
	 [***]
	  	2
		
	 [***]
	  	2
		
	 [***]
	  	1
		
	 [***]
	  	1
		
	 [***]
	  	1
		
	 [***]
	  	1

 Shared UTHealth Equipment Outside the cGMP Production Suites 

[***] 

  
  

Page 12 

 Execution Copy 
  

 EXHIBIT B 

Immatics Equipment 
  

					
	 Immatics Equipment to be Installed in
the cGMP Production
Suites*
	  	 Number per suite
	  	 Notes

	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 Immatics Equipment to be Installed Outside of
the cGMP Production
Suites*
	  	 Number
	  	 Notes

	 [***]
	  	[***]	  	[***]
	  
 [***]
	  	  
 [***]

  

	*	 Equipment type and number may need to be modified based on Manufacturing Process changes. All equipment needs
to be approved by Facility Director and purchased from vendors qualified by the Facility. Budget modification need to be approved by UTHealth as amendments to the Agreement. 

  
  

Page 13 

 Execution Copy 
  

 EXHIBIT C 

Manufacturing Program — ACTengine ([***]) 

Disclaimer: This is a draft manufacturing process. It may be changed / amended during process development. Changes will be reviewed with Facility Director to
ensure compliance to Facility QMS and relevant regulations. Budget modification must be approved by UTHealth as Amendments to the Agreement. 

[***] 

  
  

Page 14 

 Execution Copy 

EXHIBIT C - Continued 
  

 Manufacturing Program — ACTolog ([***]) 

Disclaimer: This is the current process established by [***]. It may be changed / amended during process development. Changes will be reviewed
with Facility Director to ensure compliance to Facility QMS and relevant regulations. 
 [***] 

  
  

Page 15 

 Execution Copy 

EXHIBIT C - Continued 

Manufacturing Program — ACTolog ([***])—continued 
  

 Disclaimer: This is the current process established by [***]. It may be changed / amended as
needed during process development. Changes will be reviewed with Facility Director to ensure compliance to Facility QMS and relevant regulations. Budget modification must be approved by UTHealth as Amendments to the Agreement. 

[***] 

  
  

Page 16 

 Execution Copy 
  

 EXHIBIT D 

Consumables and Services provided to Immatics by UTHealth 

[***] 
 Immatics will supply to UTHealth copies of all standard
operating procedures used in the Licensed Facilities and Certificates of Analysis of reagents and raw materials used in the Manufacturing Program. These documents will be reviewed by Facility’s quality team and will be added to the
Facility’s Quality Management System upon approval. 

  
  

Page 17 

 Execution Copy 
  

 EXHIBIT E 

[***] 

  
  

Page 18 

 Execution Copy 
  

 [***] 

  
  

Page 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]